(Press-News.org) Highlights
Compared with kidney transplant recipients who did not receive sodium-glucose cotransporter-2 inhibitors, those treated with the medications had lower risks of experiencing kidney transplant failure, kidney transplant rejection, major adverse cardiac events, all-cause mortality, and genitourinary infections.
Results from the study will be presented at ASN Kidney Week 2023 November 1–November 5.
Philadelphia, PA (November 4, 2023) — Sodium-glucose cotransporter-2 (SGLT2) inhibitors lower blood sugar levels and have additional beneficial effects on kidney and heart health for individuals with and without diabetes, but little is known about the safety and efficacy of these medications in kidney transplant recipients. Research that examined this will be presented at ASN Kidney Week 2023 November 1–November 5.
For the study, investigators analyzed the electronic medical records of 3,450 adult kidney transplant recipients treated with SGLT2 inhibitors who were matched to 3,450 similar patients who did not receive SGLT2 inhibitors, using a statistical technique called propensity matching adjusted for demographic data, baseline heart disease and blood test.
Kidney transplant patients treated with SGLT2 inhibitors were 59%, 64%, 33%, and 40% less likely to experience kidney transplant rejection, kidney transplant failure, major adverse cardiac events, and mortality, respectively, over 3 years. They were also 44% less likely to experience urinary tract infections.
“To date, all major SGLT2 inhibitor studies have excluded kidney transplant patients. This study was the largest observational study demonstrating the benefits of SGLT2 inhibitors in patients with kidney transplants,” said corresponding author Nageen, Anwar, MD, of the Liverpool University Hospitals NHS Foundation Trust. “This study is a big step towards qualifying transplant patients to benefit from the many positive effects of SGLT2 inhibitor use and sets the precedence for a randomized controlled trial to evaluate the long-term kidney and cardiovascular outcomes of SGLT2 inhibitor therapy in kidney transplant patients.”
Study: “Outcomes Associated with Sodium-Glucose Cotransporter-2 Inhibitors in Kidney Transplant Recipients: A Real-World Analysis Using a Global Federated Database”
The world's premier nephrology meeting, ASN Kidney Week, brings together approximately 12,000 kidney professionals from across the world. The largest nephrology meeting provides participants with exciting and challenging opportunities to exchange knowledge, learn the latest scientific and medical advances, and listen to engaging and provocative discussions with leading experts in the field.
About ASN
Since 1966, ASN has been leading the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge and advocating for the highest quality care for patients. ASN has nearly 21,000 members representing 140 countries. For more information, visit www.asn-online.org and follow us on Facebook, X, LinkedIn, and Instagram.
# # #
END
About The Study: The findings of this diagnostic study including 43,000 individuals undergoing hereditary cancer testing demonstrate that the ability to perform RNA sequencing concurrently with DNA sequencing represents an important advancement in germline genetic testing by improving detection of novel variants and classification of existing variants. This expands the identification of individuals with hereditary cancer predisposition and increases opportunities for personalization of therapeutics and surveillance.
Authors: Rachid Karam, M.D., Ph.D., of Ambry Genetics ...
Melon (Cucumis melo L.) is an important vegetable crop that has an extensive history of cultivation, and has been classified into two subspecies, C. melo ssp. agrestis and C. melo ssp. melo. Previous study suggested that the two subspecies were domesticated independently [1], which may have generated different genetic mechanisms for the same trait between the two subspecies. Furthermore, the difference in their geographical distribution resulted in diverse characteristics between the two subspecies, shaping genomic imprinting in their genomes. Wild germplasm is an important genetic resource in crop breeding because of its high genetic diversity ...
Pregnant women living in blighted neighborhoods with high levels of known stressors have higher levels of testosterone – the primary sex hormone in males -- which disrupt hormone regulation and may lead to life-threatening complications during and after childbirth, according to Rutgers research.
“Previous research has shown that exposure to neighborhood stressors is associated with preterm birth, low birth weight and other complications such as preeclampsia, gestational diabetes and stillbirth,” ...
Highlights
Investigators have found demographic differences between participants of kidney transplant clinical trials and transplant recipients in the United States, even in recent years.
Results from the study will be presented at ASN Kidney Week 2023 November 1–November 5.
Philadelphia, PA (November 3, 2023) — Investigators recently examined the extent to which participants in clinical trials related to kidney transplantation are similar to individuals undergoing transplantation in the United States. The ...
Highlights
In a recent analysis of US data, Black patients with kidney failure experienced survival advantages compared with White patients when county-level structural racism was low, but they experienced survival disadvantages compared with White patients at higher levels of structural racism.
Results from the study will be presented at ASN Kidney Week 2023 November 1–November 5.
Philadelphia, PA (November 3, 2023) — A new analysis indicates that county-level structural racism is a significant determinant of death among individuals ...
Highlights
Imaging tests in individuals with type 2 diabetes without symptoms of cardiovascular disease indicated that elevated albumin in the urine may be linked with sub-clinical coronary artery pathology, including coronary artery microcalcifications.
Results from the study will be presented at ASN Kidney Week 2023 November 1–November 5.
Philadelphia, PA (November 3, 2023) — Advances in non-invasive imaging have allowed clinicians to assess both the structure and function of coronary arteries. Investigators who recently used positron emission tomography and computed tomography ...
Highlights
By examining the gene expression patterns of single cells from human fetal kidneys, researchers created a map that demonstrates the trajectories of cell states in the developing kidney and that identifies characteristics associated with kidney diseases.
Results from the study will be presented at ASN Kidney Week 2023 November 1–November 5.
Philadelphia, PA (November 3, 2023) — Scientists have examined the gene expression patterns of single cells from 5 human fetal kidneys to create the most complete atlas of the ...
Highlights
Results from the phase 3 SCORED trial indicate that sotagliflozin protects kidney and heart health in individuals with type 2 diabetes and chronic kidney disease.
Results from the study will be presented at ASN Kidney Week 2023 November 1–November 5.
Philadelphia, PA (November 3, 2023) — Sodium-glucose cotransporter-2 (SGLT2) inhibitors, which are medications that lower blood sugar levels among other effects, provide kidney- and heart-related benefits to patients with and without diabetes. An exploratory analysis ...
Alaskans and visitors may be able to see an artificial airglow in the sky created by the High-frequency Active Auroral Research Program during a four-day research campaign that starts Saturday.
Scientists from the University of Alaska Fairbanks, Cornell University, University of Colorado Denver, University of Florida and Georgia Institute of Technology will conduct a variety of experiments at the UAF-operated research site.
The experiments will focus on the ionosphere, the region of the atmosphere between about 30 and 350 miles ...
“The patient was managed with ripretinib and surgical resection of progressing lesions at multiple time points which led to extended clinical benefit.”
BUFFALO, NY- November 3, 2023 – A new case report was published in Oncoscience (Volume 10) on September 20, 2023, entitled, “Multi-disciplinary management of recurrent gastrointestinal stromal tumor harboring KIT exon 11 mutation with the switch-control kinase inhibitor ripretinib and surgery.”
Ripretinib is a tyrosine kinase inhibitor that was approved by the United States FDA in 2020 for treatment of advanced ...
